
CLAIMS

1. A compound represented by the formula:

[Chem. 1]



(A)

2. The compound as claimed in claim 1, which is crystalline.

3. The compound as claimed in claim 2, which has characteristic peaks at diffraction angles (2θ(°)) of 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5 and 26.2 in a powder X-ray diffraction diagram.

4. The compound as claimed in claim 2, which has characteristic peaks at chemical shift values (δ(ppm)) of 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1 and 55.5 in a ^{13}C solid-state NMR spectrum chart.

5. The compound as claimed in claim 2, which has characteristic peaks at chemical shift values (δ(ppm)) of -131.6, -145.2 and -151.8 in a ^{19}F solid-state NMR spectrum chart.

6. The compound as claimed in any one of claims 2 to 5, which has an endothermic peak at around 213°C in a differential thermal analysis chart.

7. A pharmaceutical composition which comprises as an active ingredient a compound as claimed in any one of claims 1 to 6.

8. The pharmaceutical composition as claimed in claim 7, which is a gonadotropin releasing hormone antagonist.

9. The pharmaceutical composition as claimed in claim 7, which is an agent for the prevention or treatment of a sex hormone-dependent disease, a reproduction regulator, a contraceptive, an ovulation inducing agent, or an agent for the prevention of post-operative recurrence of sex hormone-dependent cancers.


10. A use of a compound as claimed in any one of claims 1 to 6 for the manufacture of an agent for the prevention or treatment of a sex hormone-dependent disease, a reproduction regulator, a contraceptive, an ovulation inducing agent or an agent for the prevention of post-operative recurrence of sex hormone-dependent cancers.

11. A method for preventing or treating a sex hormone-dependent disease, a reproductive regulating method, a contraceptive method, an ovulation-inducing method, or a method for prevention of post-operative recurrence of sex hormone-dependent cancers, comprising administering an effective amount of a compound as claimed in any one of claims 1 to 6.

CLAIMS

1. A compound represented by the formula:

[Chem. 1]



(A)

2. The compound as claimed in claim 1, which is crystalline.

3. The compound as claimed in claim 2, which has characteristic peaks at diffraction angles (2θ(°)) of 7.1, 11.5, 19.4, 20.3, 21.5, 22.0, 22.6, 23.5 and 26.2 in a powder X-ray diffraction diagram.

4. The compound as claimed in claim 2, which has characteristic peaks at chemical shift values (δ(ppm)) of 155.8, 149.8, 145.3, 118.0, 113.7, 111.6, 110.3, 98.1, 69.8, 58.7, 57.1 and 55.5 in a ^{13}C solid-state NMR spectrum chart.

5. The compound as claimed in claim 2, which has characteristic peaks at chemical shift values (δ(ppm)) of -131.6, -145.2 and -151.8 in a ^{19}F solid-state NMR spectrum chart.

6. The compound as claimed in any one of claims 2 to 5, which has an endothermic peak at around 213°C in a differential thermal analysis chart.

7. A pharmaceutical composition which comprises as an active ingredient a compound as claimed in any one of claims 1 to 6.

8. The pharmaceutical composition as claimed in claim 7, which is a gonadotropin releasing hormone antagonist.